Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Manheim

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
The Lancet. Infectious Diseases|August 16, 2020
Evolving ethics of COVID-19 challenge trialsDavid Manheim,
Patterns (New York, N.Y.)|October 25, 2023
Building less-flawed metrics: Understanding and creating better measurement and incentive systemsDavid Manheim
Health Security|November 30, 2018
Questioning Estimates of Natural Pandemic RiskDavid Manheim
F1000Research|August 1, 2022
High-risk human-caused pathogen exposure events from 1975-2016David Manheim, Gregory Lewis
F1000Research|January 28, 2021
Option-based guarantees to accelerate urgent, high-risk vaccines: a new market-shaping approachDavid Manheim, Derek Foster
Disaster Medicine and Public Health Preparedness|October 22, 2020
The Structure of Tweets About Vaccine Safety Between Health Organizations, Experts, and the Public: Analyzing Risk Communication ConversationsDavid Manheim, Anat Gesser-Edelsburg
Risk Analysis : an Official Publication of the Society for Risk Analysis|May 4, 2021
Exploring Risks of Human Challenge Trials For COVID-19David Manheim, Witold Wiȩcek, Virginia Schmit, et al.
Rand Health Quarterly|December 19, 2025
Understanding the Theoretical Limits of AI-Enabled Pathogen Design: Insights from a Delphi StudyDavid Manheim, Adeline Williams, Casey Aveggio, et al.
Expert Opinion on Drug Discovery|March 19, 2013
SiDMAP: a metabolomics approach to assess the effects of drug candidates on the dynamic properties of biochemical pathwaysGreg Maguire, Paul Lee, David Manheim, et al.
Health Security|January 11, 2023
Managing the Transition to Widespread Metagenomic Monitoring: Policy Considerations for Future BiosurveillanceChelsea Liang, James Wagstaff, Noga Aharony, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
The Lancet. Infectious Diseases|August 16, 2020
Evolving ethics of COVID-19 challenge trialsDavid Manheim,
Patterns (New York, N.Y.)|October 25, 2023
Building less-flawed metrics: Understanding and creating better measurement and incentive systemsDavid Manheim
Health Security|November 30, 2018
Questioning Estimates of Natural Pandemic RiskDavid Manheim
F1000Research|August 1, 2022
High-risk human-caused pathogen exposure events from 1975-2016David Manheim, Gregory Lewis
F1000Research|January 28, 2021
Option-based guarantees to accelerate urgent, high-risk vaccines: a new market-shaping approachDavid Manheim, Derek Foster
Disaster Medicine and Public Health Preparedness|October 22, 2020
The Structure of Tweets About Vaccine Safety Between Health Organizations, Experts, and the Public: Analyzing Risk Communication ConversationsDavid Manheim, Anat Gesser-Edelsburg
Risk Analysis : an Official Publication of the Society for Risk Analysis|May 4, 2021
Exploring Risks of Human Challenge Trials For COVID-19David Manheim, Witold Wiȩcek, Virginia Schmit, et al.
Rand Health Quarterly|December 19, 2025
Understanding the Theoretical Limits of AI-Enabled Pathogen Design: Insights from a Delphi StudyDavid Manheim, Adeline Williams, Casey Aveggio, et al.
Expert Opinion on Drug Discovery|March 19, 2013
SiDMAP: a metabolomics approach to assess the effects of drug candidates on the dynamic properties of biochemical pathwaysGreg Maguire, Paul Lee, David Manheim, et al.
Health Security|January 11, 2023
Managing the Transition to Widespread Metagenomic Monitoring: Policy Considerations for Future BiosurveillanceChelsea Liang, James Wagstaff, Noga Aharony, et al.
Pageof 2